Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
OZEMPIC approved in the USA and positive CHMP opinion
issued in the EU
OzempicⓇ label in the USA
Efficacy
•
Conve-
nience
.
Safety
•
Slide 11
CHMP endorsed inclusion of CV data
from SUSTAIN 6 trial in Ozempic® EU label
Reduction in HbA1c VS comparators¹
Reduction in body weight vs comparators¹
Administered once-weekly
To be launched in the OzempicⓇ pen
Guidance on retinopathy similar to wording
in insulin labels
Cardiovascular safety with number of MACE
events in clinical section
Trial
Patients
Reference to
CV results
in indication
MACE
Kaplan-Meier
OzempicⓇ label
recommended
VictozaⓇ label
SUSTAIN 6
LEADER
3,297
9,340
Recommended
Included
HR: 0.741
HR: 0.872
Recommended
Included
1 Statistically significant reduction compared to comparators: placebo, sitagliptin, exenatide extended-
release and insulin glargine U100 (phase 3a SUSTAIN trial programme)
195% confidence interval [0.58;0.95]. 295% confidence interval [0.78;0.97]
CV: Cardiovascular; MACE: Major adverse cardiovascular events; HR: Hazard ratio
changing
diabetes®
novo nordiskView entire presentation